• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[尿路上皮癌]

[Urothelial carcinoma].

作者信息

Rübben H, Vom Dorp F

机构信息

Klinik und Poliklinik für Urologie, Universitätsklinikum Essen, Hufelandstrasse 55, Essen, Germany.

出版信息

Urologe A. 2011 Sep;50 Suppl 1:176-8. doi: 10.1007/s00120-011-2669-5.

DOI:10.1007/s00120-011-2669-5
PMID:21837494
Abstract

Various study groups are working on the WHO classification of 2004 which eliminates the previous grades of differentiation G1, G2, and G3 and classifies non-muscle-invasive bladder cancer into genetically stable low-grade and genetically unstable high-grade urothelial carcinomas. In muscle-invasive bladder cancer, extended lymph node dissection as part of radical cystectomy should remain the standard procedure for now.

摘要

多个研究小组正在研究世界卫生组织2004年的分类方法,该方法取消了之前的分化等级G1、G2和G3,并将非肌层浸润性膀胱癌分为基因稳定的低级别和基因不稳定的高级别尿路上皮癌。在肌层浸润性膀胱癌中,作为根治性膀胱切除术一部分的扩大淋巴结清扫目前仍应是标准手术。

相似文献

1
[Urothelial carcinoma].[尿路上皮癌]
Urologe A. 2011 Sep;50 Suppl 1:176-8. doi: 10.1007/s00120-011-2669-5.
2
Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.脉管浸润、输尿管再植和膀胱癌病史与盆腔淋巴结阴性的肌层浸润性膀胱癌行部分膀胱切除术的不良预后相关。
Eur J Surg Oncol. 2013 Oct;39(10):1150-6. doi: 10.1016/j.ejso.2013.04.006. Epub 2013 May 27.
3
Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.根治性膀胱切除术和扩大盆腔淋巴结清扫术:仅接受手术治疗的髂总血管分叉以上淋巴结转移患者的生存率。
J Urol. 2007 Oct;178(4 Pt 1):1218-23; discussion 1223-4. doi: 10.1016/j.juro.2007.05.160. Epub 2007 Aug 14.
4
Outcome of patients undergoing radical cystectomy for invasive bladder cancer.接受根治性膀胱切除术治疗浸润性膀胱癌患者的治疗结果。
Front Radiat Ther Oncol. 2002;36:106-17. doi: 10.1159/000061335.
5
Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.在根治性膀胱切除术的 pT1 尿路上皮癌患者中,联合免疫组化标志物的预测价值。
J Urol. 2009 Jul;182(1):78-84; discussion 84. doi: 10.1016/j.juro.2009.02.125. Epub 2009 May 17.
6
[Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].[根治性膀胱切除术治疗浸润性膀胱癌的结果,特别提及根据尿流改道类型的预后因素和生活质量]
Ann Acad Med Stetin. 2000;46:217-29.
7
[The importance of lymphadenectomy for muscle invasive transitional cell carcinoma of the human bladder - a review of the literature].
Aktuelle Urol. 2011 Mar;42(2):115-21. doi: 10.1055/s-0031-1271411. Epub 2011 Mar 24.
8
Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.首次就诊时根据膀胱癌肿瘤分期的根治性膀胱切除术后生存率。
Urol Int. 2004;72(2):103-11. doi: 10.1159/000075962.
9
The role of lymphadenectomy in high-grade invasive bladder cancer.淋巴结清扫术在高级别浸润性膀胱癌中的作用。
Urol Clin North Am. 2005 May;32(2):187-97. doi: 10.1016/j.ucl.2005.01.005.
10
Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes.美国癌症联合委员会病理分期T3a与T3b尿路上皮癌的比较:患者预后分析
Cancer. 2009 Feb 15;115(4):770-5. doi: 10.1002/cncr.24110.

引用本文的文献

1
A Primary Urothelial Carcinoma Presenting as a Mid-Bulbar Urethral Stricture in a 30-Year-Old Male.一名30岁男性原发性尿路上皮癌表现为球部中段尿道狭窄
Cureus. 2021 Jul 31;13(7):e16774. doi: 10.7759/cureus.16774. eCollection 2021 Jul.

本文引用的文献

1
Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial.5-氨基酮戊酸诱导荧光膀胱镜检测膀胱癌及其临床转归:一项多中心、随机、双盲、安慰剂对照研究。
Cancer. 2011 Mar 1;117(5):938-47. doi: 10.1002/cncr.25523. Epub 2010 Nov 8.
2
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.氨己烯酸荧光膀胱镜检查降低非肌层浸润性膀胱癌患者的复发率。
J Urol. 2010 Nov;184(5):1907-13. doi: 10.1016/j.juro.2010.06.148. Epub 2010 Sep 17.
3
Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer.
分子分级(FGFR3/MIB-1)和 EORTC 风险评分可预测原发性非肌肉浸润性膀胱癌。
Eur Urol. 2010 Sep;58(3):433-41. doi: 10.1016/j.eururo.2010.05.043. Epub 2010 Jun 9.
4
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome.AJCC pT2 膀胱癌亚分期的验证:深肌层浸润与预后显著相关。
Eur Urol. 2010 Jul;58(1):112-7. doi: 10.1016/j.eururo.2010.01.015. Epub 2010 Jan 20.
5
Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.经尿道膀胱移行细胞非肌肉浸润性肿瘤切除术联合或不联合 5-氨基酮戊酸在可见和荧光光下的应用:一项前瞻性、随机、多中心研究的结果。
Eur Urol. 2010 Feb;57(2):293-9. doi: 10.1016/j.eururo.2009.10.030. Epub 2009 Nov 6.
6
A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder.一种新的多模态技术可精确绘制膀胱的主要淋巴定植部位。
Eur Urol. 2010 Feb;57(2):205-11. doi: 10.1016/j.eururo.2009.10.026. Epub 2009 Oct 23.
7
Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.氨基酮戊酸光动力诊断辅助经尿道膀胱肿瘤切除术治疗后,肿瘤残留和复发率与 5-氨基酮戊酸相当。
Urology. 2009 Dec;74(6):1282-6. doi: 10.1016/j.urology.2009.06.088. Epub 2009 Oct 12.
8
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.接受根治性膀胱切除术治疗的临床 T1 级 3 级尿路上皮癌患者的特征和结局:来自国际队列的结果。
Eur Urol. 2010 Feb;57(2):300-9. doi: 10.1016/j.eururo.2009.09.024. Epub 2009 Sep 12.
9
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.当代一组临床 T1 膀胱癌重新分期患者的临床结局。
Eur Urol. 2009 Dec;56(6):903-10. doi: 10.1016/j.eururo.2009.07.005. Epub 2009 Jul 17.
10
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.一项针对非肌层浸润性膀胱癌患者,比较膀胱内注射丝裂霉素C与卡介苗的随机研究长期结果的个体患者数据荟萃分析。
Eur Urol. 2009 Aug;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038. Epub 2009 Apr 24.